PureTech Health Says LYT-200 Shows Favorable Tolerability And Efficacy In Phase 1b Trial
ReutersDec 5, 2025 7:08 PM
Dec 5 (Reuters) - PureTech Health PLC PRTC.L:
PURETECH’S FOUNDED ENTITY GALLOP ONCOLOGY ANNOUNCES POSITIVE INITIAL TOPLINE DATA FROM PHASE 1B TRIAL OF LYT-200 IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROME
PURETECH HEALTH - LYT-200 SHOWS FAVORABLE TOLERABILITY AND EFFICACY IN PHASE 1B TRIAL
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
US November Non-Farm Payrolls and CPI data both loom【The week ahead】
TradingKey - On the equities front, Micron Technology, Nike, Accenture, FedEx, and other companies will release earnings. Following significant volatility in AI-related stocks, Micron Technology's earnings performance is receiving particular market attention.TradingKey
14 hours ago
Netflix Stock Analysis: Why Netflix Stock Keeps Falling, and When Should Investors Buy Netflix Stock?
While the final terms for Netflix's acquisition of WBD remain uncertain in the short term, we view the recent decline, driven by market sentiment, as a significant long-term undervalued opportunity. The return to more realistic valuations enhances the investment appeal of Netflix stock.TradingKey
15 hours ago
Why Is the "Altcoin Season" Delayed? Will Altcoins Perish?
The anticipated "altcoin season" has yet to materialize, constrained by a lack of fresh market capital and Bitcoin's continued dominance in absorbing available funds. This does not mean all altcoins will perish; however, a segment of these tokens will gradually exit the market. Therefore, caution isTradingKey
Wed, Dec 10
Gold Price Steady Climb and the Sudden Surge of Silver and Copper: Will Their Bull Run Extend Into 2026?
Dow Jones Market Data shows this marks the first time since 1980all three metals—gold, silver, and copper—simultaneously refreshed their all-time highs in the same year. Will this rally extend into 2026?TradingKey
Wed, Dec 10
Why Did Strategy's Stock Price Plummet? Can MSTR Reach $1,000?
MicroStrategy (MSTR) stock, despite pressures from Bitcoin volatility and its weak core business, represents the most leveraged investment in a Bitcoin bull market. The company's stock path to $1,000 largely depends on Bitcoin's market performance. Major institutions, including Standard Chartered anTradingKey
Thu, Dec 4
Tradingkey
